Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Merger or Acquisition (August 2023)
6 slides from Royalty Pharma's merger presentation, August 2023
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Royalty acquisition
royalty acquisition August 2023
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Adstiladrin is an attractive asset with blockbuster potential
Adstiladrin is an attractive asset with blockbuster potential 1 2 3 FDA approved gene NCCN guidelines Pricing therapy for bladder cancer support broad usage Adstiladrin is a gene therapy approved NCCN guideline inclusion occurred two Extensive RP market research supports in December 2022 for high-ri
Slide 5: Adstiladrin has an overall compelling clinical profile
Adstiladrin has an overall compelling clinical profile Keytruda is the only other approved therapy for high-risk, BCG-unresponsive NMIBC patients Adstiladrin(1) Keytruda(2) 53% complete response 41% complete response Efficacy Efficacy at 3 months (single dose) at 3 months Serious AEs: 11% Serious AE
Slide 6: Significant market opportunity in NMIBC
Significant market opportunity in NMIBC Non-muscle invasive bladder cancer (NMIBC) (Patients in the U.S.) • RP market research supports significant physician enthusiasm for an efficacious, safe and convenient therapy for this disease ~82,000 New bladder cancer • Potential for Adstiladrin to become f
Royalty Pharma — Merger or Acquisition (August 2023) on 6ix